Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$1.02 USD
-0.01 (-0.97%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.02 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ONCY 1.02 -0.01(-0.97%)
Will ONCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ONCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ONCY
Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
ONCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Novartis (NVS) to Report Q1 Earnings: What to Expect?
After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)
Other News for ONCY
Oncolytics Biotech Highlights at Growth Conference
Oncolytics Biotech? to Participate in a Fireside Chat at Canaccord Genuity's 44th Annual Growth Conference
Buy Rating on Oncolytics Biotech Backed by Strong Clinical Trials and Strategic Partnerships
Oncolytics Biotech Announces Equity Distribution Deal
Oncolytics Biotech Inc (ONCY) Q2 2024 Earnings Call Transcript Highlights: Financial Stability ...